Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- CRDL
- Price
- 1.04
- Stock movement up
- +- (0.00%)
- Company name
- Cardiol Therapeutics Inc Class A
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Drug Manufacturers - Specialty & Generic
- Market cap
- 116.15M
- Ent value
- 107.91M
- Price/Sales
- -
- Price/Book
- 12.15
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -0.62%
- 1 year return (CAGR)
- -16.13%
- 3 year return (CAGR)
- 15.79%
- 5 year return (CAGR)
- -25.40%
- 10 year return (CAGR)
- -
Last updated: 2026-03-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
CRDL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 12.15 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 111.68M |
| EPS (TTM) | -0.38 |
| FCF per share (TTM) | -0.29 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -33.70K |
| Operating income (TTM) | -33.23M |
| Net income (TTM) | -32.29M |
| EPS (TTM) | -0.38 |
| EPS (1y forward) | -0.36 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 11.62M |
| Net receivables | 195.88K |
| Total current assets | 12.81M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 989.65K |
| Total assets | 12.95M |
| Accounts payable | 0.00 |
| Short/Current long term debt | 134.20K |
| Total current liabilities | 3.29M |
| Total liabilities | 3.39M |
| Shareholder's equity | 9.56M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -24.22M |
| Capital expenditures (TTM) | 27.55K |
| Free cash flow (TTM) | -24.25M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -337.72% |
| Return on Assets | -249.38% |
| Return on Invested Capital | -336.43% |
| Cash Return on Invested Capital | -252.66% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.03 |
| Daily high | 1.06 |
| Daily low | 1.01 |
| Daily Volume | 188K |
| All-time high | 8.13 |
| 1y analyst estimate | 7.50 |
| Beta | 0.73 |
| EPS (TTM) | -0.38 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 1 Apr 2026 |
Downside potential
Loading...
Downside potential data
| CRDL | S&P500 | |
| Current price drop from All-time high | -87.21% | -1.82% |
| Highest price drop | -94.45% | -56.47% |
| Date of highest drop | 5 Apr 2023 | 9 Mar 2009 |
| Avg drop from high | -71.70% | -10.84% |
| Avg time to new high | 119 days | 12 days |
| Max time to new high | 1753 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
116.15M
Marketcap category
Small-cap
Description
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
Employees
18
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page